[1] 潘剑,王杞章,刘济远.双膦酸盐相关性颌骨坏死[J].华西口腔医学杂志, 2017, 35(1): 29-36. [2] 袁仕廷, 任仪鹏, 陶冶, 等. 双膦酸盐相关性颌骨坏死的临床治疗[J]. 中华老年口腔医学杂, 2018, 16(5): 286-290. [3] Yang R, Tao Y, Wang C, et al.Circulating microRNA panel as a novel biomarker to diagnose bisphosphonate-related osteonecrosis of the jaw[J]. Int J Med Sci, 2018, 15(14): 1694-1701. [4] Marx RE.Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61(9): 1115-1117. [5] Manzano-Moreno FJ, Ramos-Torrecillas J, Mekuizo-Ro-driguez L, et al. Bisphosphonate modulation of the Gene expression of different markers involved in osteoblast physiology possible implications in bisphosphonate-related osteonecrosis of the jaw[J]. Int J Med Sci, 2018, 15(4): 359-367. [6] Ruggiero SL, Dodson TB, Fantasia J, et al.American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw-2014 update[J]. J Oral Maxillofac Surg, 2014, 72(10): 1938-1956. [7] Ruggireo SL, Mehrotra B, Rosenberg TJ, et al.Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases[J]. J Oral Maxillofac Surg, 2004, 62(5):527-534. [8] Ruggiero SL, Dodson TB, Assael LA, et al.American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update[J]. J Oral Maxillofac Surg, 2009, 67(5 Suppl): 2-12. [9] Migliario M, Mergoni G, Vescovi P, et al.Osteonecrosis of the Jaw (ONJ) in osteoporosis patients:report of delayed diagnosis of a multisite case and commentary about risks coming from a restricted ONJ definition[J]. Dent J(Basel), 2017, 5(1): 13-22. [10] Colella G, Campisi G, Fusco V, et al.American Association of Oral and Maxillofacial Surgeons position paper: bisphos-phonate-related osteonecrosis of the jaws-2009 update: the need to refine the BRONJ definiti-on[J]. J Oral Maxillofac Surg, 2009, 67(12): 2698-2699. [11] 龚佳幸, 王慧明. 二膦酸盐相关性颌骨骨坏死的临床分析[J].华西口腔医学志, 2016, 34(4): 358-363. [12] 殷学民,王方圆. 双膦酸盐性颌骨坏死的临床诊断与治疗[J].口腔疾病防治, 2017, 25(3): 137-142. [13] 黄英, 张慧, 蔡跃, 等. 缺牙区松质骨密度的定量CT法测量[J]. 中国组织工程研究, 2017, 21(36): 5775-5780. [14] 章斌, 田泾, 金剑. 唑来膦酸致多发性骨髓瘤患者下颌骨坏死1例报告与分析[J]. 上海医药, 2017, 38(19): 3-5. [15] Kim DS, Kim JH, Ohe JY, et al.Bisphosphonate-related osteonecrosis of the jaw in a patient with osteoporosis following treatment of testicular cancer: a case report[J]. J Korean Assoc Oral Maxillofac Surg, 2015, 41(6): 327-331. [16] Silva ML, Tasso L, Azambuja AA, et al.Effect of hyperbaric oxygen therapy on toothextraction sites in rats subjected to bisphosphonate therapy-histomorphometric and immunohisto chemical analysis[J]. Clin Oral Investig, 2017, 21(1): 199-210. [17] Kim KM, Park W, Oh SY, et al.Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw[J]. Osteoporos Int, 2014, 25(5):1625-1632. [18] Cheung A, Seeman E.Teriparatide therapy for alendronate-associated osteonecrosis of the jaw[J]. N Engl J Med, 2010, 363(25): 2473-2474. [19] 王杞章,刘济远,潘剑.药物性颌骨坏死的研究进展[J]. 华西口腔医学杂志, 2018, 36(5): 568-572. [20] Khan AA, Morrison A, Hanley DA, et al.Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus[J]. J Bone Miner Res, 2015, 30(1): 3-23. [21] Chang JI, Hazboun RC, Chang TI.Incongruities in the AAOMS position paper: medication-related osteonecrosis of the jaw-2014 update[J]. J Oral Maxillofac Surg, 2014, 72(12): 2381-2389. [22] Heim N, Götz W, Kramer FJ, et al.Antiresorptive drug-related changes of the mandibular bone densitiy in medication-related osteonecrosis of the jaw?patients[J]. Dentomaxillofac Radiol, 2019, 48(8): 20190132. |